Plain-English translation of NCT06912165 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called WD-890 to see if it can help people with moderate to severe plaque psoriasis—a skin condition that causes thick, red, scaly patches. About 140 people will participate, and roughly half will receive the medication while the other half receive a placebo (a dummy pill) to see how well the treatment actually works. The study will last 24 weeks total, including time to check if the medication is safe and effective.
Plaque psoriasis can be painful, itchy, and difficult to treat with existing options. Researchers are testing this medication to see if it offers patients a new, potentially better way to control their symptoms and improve their quality of life.
You likely qualify if…
You likely don't qualify if…
You will visit the study center several times over 24 weeks. First, there's a screening visit (within 4 weeks) where doctors will confirm you qualify. Then you'll take a daily tablet—either the new medication at one of three doses or a placebo—for 16 weeks while the study team monitors how well it works and checks for side effects. After you stop taking the medication, you'll have one final follow-up visit 4 weeks later to make sure you're doing well.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Zhejiang Wenda Pharma Technology LTD.
Enrollment target
~140 participants
Started
December 2024
Primary completion
October 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qianjin Lu, doctor
Zhejiang Wenda Pharma Technology LTD.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.